Navigation Links
Novartis's Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function
Date:7/29/2013

BURLINGTON, Mass., July 29, 2013 /PRNewswire/ --  Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical trial data and thought leader opinion, Novartis's novel vasodilative therapy serelaxin has the potential to gain acceptance among cardiologists for the treatment of acute heart failure, given that it is predicted to reduce mortality and prevent worsening renal function. While cardiologists are most compelled by drugs that reduce patient mortality, the high price of novel acute heart failure treatments could offset cardiologist receptivity to such agents. Payers also indicate that they would only accommodate such high price premiums in the presence of substantial improvements in efficacy. Cardiorentis's ularitide is similarly predicted to reduce mortality as well as offer other improvements in efficacy and safety compared to current therapies.     

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The DecisionBase 2013 report entitled Acute Heart Failure: Can the Novel Vasodilators Serelaxin and Ularitide Fulfill the Unmet Needs Highlighted by Cardiologists? also finds that U.S. cardiologists regard reductions in acute heart failure hospital readmissions as an equally pressing unmet need to reducing patient mortality. However, none of the current or emerging therapies are expected to address the issue of patient rehospitalization. Although serelaxin was associated with a non-significant increase in rehospitalization in patient trials, this agent still received the highest preference share when compared to ularitide and Scios/Johnson & Johnson's Natrecor in Decision Resources' target product profile simulator.

The findings also reveal that all of the emerging acute heart failure therapies are set to surpass many of the current therapies in terms of both efficacy and safety. In particular, surveyed cardiologists express excitement for the novel vasodilative therapies, which are also expected to provide improvements in dyspnea over the current patient-share leader, furosemide (Sanofi's Lasix/Lasilix, generics).

"In the last 20 years, many of the therapies in development for acute heart failure resulted in disappointment," said Decision Resources Analyst Joseph Dwyer, M.Res, Ph.D. "The high attrition rate for drugs in the acute heart failure pipeline is largely accounted for by improper trial design stemming from poor understanding of the disease and the lack of identification of an ideal therapeutic window. The biologic vasodilator serelaxin is set to address some of the previous failures of acute heart failure therapies, and this new agent has the potential to fulfill the largest unmet needs in this patient population and could emerge as a truly breakthrough therapy."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis
2. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
3. Cosmetic Surgery Solicitors Warn of Potential Risks Posed by Dermal Fillers
4. Signum Dermalogix Investigational New Drug (IND) Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea
5. AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
6. For Moderate to Severe Psoriasis, Thought Leaders Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies
7. Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients
8. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
9. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
11. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association ... Featuring a collection of specialty vendors and unique items from across the nation, this ... health and wellness services offered by the VNA. The boutique will be open ...
Breaking Medicine News(10 mins):